All publications
Improving the Drug Loading Capacity and Downstream Processing of HPMCAS using Gelucire® 48/16 in Hot-Melt Extrusion
CRS Annual Meeting 2026 - Jul 2026
This poster demonstrates how Gelucire® 48/16 enhances the hot-melt extrusion process, improves tabletability, and increases drug loading and release from HPMCAS-based amorphous solid dispersions.
Transcutol® V, a must-have, safe and versatile excipient for optimised veterinary medicines
International Animal Health Journal - Jul 2026
In this whitepaper, we focus on Transcutol® V, a powerful solvent, solubiliser and penetration enhancer, largely used across major animal species and in a variety of dosage forms. The main properties of Transcutol® V are described in comparison to other solvents used in veterinary medicines worldwide. Applications in oral, skin and injectable drug delivery are illustrated through market references and case studies elaborated in our Technical Centres of Excellence.
Strategic Excipient Sourcing: Navigating Supply Chain Resilience, Quality & Sustainability by Design
Drug Development & Delivery - May 2026
This article explores key considerations for selecting an excipient supplier, including supply chain resilience, quality/regulatory support, and environmental sustainability. Learn how Gattefossé is enabling next-generation therapies with localized manufacturing and sustainable, lipid-based solutions.
Transdermal ointment in cats - a promising strategy for improved compliance
EUFEPS - May 2026
In this study, we developed a placebo ointment based on Transcutol® V and Labrasol®, designed to mimic the physicochemical and rheological properties of a veterinary RLD of mirtazapine (Mirataz®).
Advantages of combining cellulosic polymers and lipids in extruded 3D printing filaments. Part II 3D printing (FDM) and printlets characterization
PBP - Mar 2026
In this second poster of this collaboration between Gattefossé, ShinEtsu and ThermoFisher, various combinations of lipid excipients and TYLOPUR® 605 (Hypromellose 2910) were extruded, printed with an active pharmaceutical ingredient (API), and comprehensively characterized.
Formulation Strategies to Improve Drug Absorption: The Role of Lipid-Based Formulations and Permeation Enhancers
PBP - Mar 2026
This work compared ticagrelor permeability in Caco-2 monolayers versus Caco-2/HT29-MTX (70:30) co-cultures to assess the impact of mucus and how lipid excipients modulate intestinal permeability.
Predicting API solubility in lipid excipients a combined PC-SAFT and experimental approach for enhanced oral delivery
PBP - Mar 2026
The study investigates the predictive ability of the PC-SAFT thermodynamic model, implemented in the Siemens gPROMS FormulatedProducts platform, to estimate drug solubility in lipid excipients.
Lipid excipients as key modulators of the apparent intestinal permeability in lipid-based formulations: Insights from Caco-2 and Caco-2/HT29-MTX models
European Journal of Pharmaceutics and Biopharmaceutics - Mar 2026
In this publication, we explore how lipid-based formulations enhance drug solubilization and permeability, and how adding permeation enhancers further boosts absorption. Mucus-containing models showed lower but more physiologically relevant permeability, underscoring the importance of excipient choice and ratios in formulation design.
Beyond the capsule: Unlocking the full potential of lipid excipients in oral solid dosage forms
Jan 2026
In this whitepaper, Gattefossé Pharmaceuticals seeks to bridge the gap between lipid-based formulations and oral solid dosage forms, demonstrating the utility and potential of incorporating lipid excipients into modern tablet development.